• Cefodizime BA1050 in Cell Assay Workflows

  2026-08-18

  Learn how Cefodizime SKU BA1050 can be incorporated into cell viability, proliferation, cytotoxicity, and bacterial co-culture workflows without confusing antimicrobial effects with direct mammalian-cell responses. This scenario-based guide connects product specifications with resistance data, solvent controls, protocol design, and practical supplier selection.

• D-Luciferin Sodium Salt for CAR-M Assays

  2026-08-18

  D-Luciferin sodium salt turns firefly luciferase expression into a dynamic readout of CAR-macrophage performance. This guide explains how to interpret ATP-dependent light signals, connect them to the latest CAR-M biology, and design more defensible oncology assays.

• Z-VAD-FMK at the Cell-Death Decision Point

  2026-08-17

  Z-VAD-FMK is more than a pan-caspase inhibitor: it is a strategic perturbation tool for distinguishing apoptotic signaling from ferroptotic and other caspase-independent outcomes. This article connects its mechanism and workflow use to recent findings on σ1R, mitochondria-associated membranes, and ferroptosis.

• Streptavidin-FITC for Glycan Adhesion Assays

  2026-08-17

  Streptavidin-FITC provides a modular route for visualizing biotinylated targets in glycan-dependent bacterial adhesion studies. This article translates ST3GAL1–Fusobacterium nucleatum findings into practical assay-design decisions for imaging, tissue analysis, and flow cytometry.

• LY2109761: A TGF-β Assay Decision Framework

  2026-08-16

  LY2109761 is a TGF-β receptor type I and II dual inhibitor suited to dissecting receptor-level control of Smad signaling, EMT, and tumor-cell behavior. This article connects its biochemical profile with pancreatic cancer assay design and the Wnt/TGF-β findings of a 2025 study.

• 0.4% Trypan Blue Solution: Practical Guide

  2026-08-15

  0.4% Trypan Blue Solution supports direct live/dead cell discrimination, routine cell counting, and membrane-integrity-based cell viability measurement in research workflows. It is intended for cell culture and cytotoxicity assays, but not for diagnostic, therapeutic, or other medical use.

• 3X (DYKDDDDK) Peptide for Assay QC

  2026-08-14

  Learn how 3X (DYKDDDDK) Peptide, SKU A6001, supports orthogonal protein-level quality control in cell viability, proliferation, and cytotoxicity workflows. This scenario-based guide covers assay compatibility, storage, metal sensitivity, interpretation, and practical vendor-selection criteria.

• 3X FLAG Peptide for Protein Workflows

  2026-08-14

  The 3X FLAG peptide streamlines competitive elution, sensitive immunodetection, and protein-quality control across recombinant protein workflows. Its small hydrophilic design is especially useful when affinity handling must be connected to membrane-protein biochemistry, structural analysis, or metal-sensitive assays.

• c-Myc tag peptide: Assay Workflow & Troubleshooting

  2026-08-13

  Use the c-Myc tag peptide as a defined competitive reagent for antibody-binding studies, immunoassay specificity controls, and selective elution of tagged fusion proteins. This workflow also shows how to connect tag-dependent measurements with transcription-factor stability studies without confusing an assay reagent with a cellular c-MYC inhibitor.

• Patient-Derived Gastric Cancer Assembloids

  2026-08-13

  Shapira-Netanelov and colleagues developed a patient-derived gastric cancer assembloid that combines matched tumor organoids with stromal subpopulations from the same tumor. The model reproduced tumor–stroma-associated transcriptional changes and revealed that stromal composition can substantially alter drug sensitivity, supporting more physiologically relevant personalized treatment studies.

• E-64 and Cathepsins in Salt-Sensitive Hypertension

  2026-08-12

  Blass and colleagues tested chronic broad cysteine cathepsin inhibition in Dahl salt-sensitive rats, combining high-salt hypertension with E-64 infusion, podocyte calcium imaging, and protein analysis. E-64 did not prevent hypertension, albuminuria, kidney damage, or altered basal podocyte calcium under the experimental conditions, providing an important negative result for interpreting cathepsin biology in renal disease.

• Selective Autophagy Tunes IRF3 and Type I IFN

  2026-08-12

  Wu and colleagues show that CALCOCO2/NDP52-mediated selective autophagy controls IRF3 stability according to viral burden, while PSMD14 preserves IRF3 by removing K27-linked ubiquitin chains at lysine 313. The work defines a regulatory axis that limits excessive antiviral signaling without eliminating the basal IRF3 required for type I interferon production.

• Deferiprone: Iron Stress to Translational Strategy

  2026-08-11

  Deferiprone, or 3-hydroxy-1,2-dimethylpyridin-4-one, is more than an iron-chelating reagent: it is a controllable perturbation tool for connecting iron availability with metabolism, proliferation, inflammation, and oxidative stress. This thought-leadership guide translates recent enterocyte findings into practical strategies for cancer biology, vascular research, and translational assay design.

• CUDC-907 Protocol and QC Guide

  2026-08-11

  CUDC-907 (SKU A4097) is a dual PI3K and HDAC inhibitor for controlled studies of PI3K/AKT signaling, histone acetylation, cell-cycle progression, and apoptosis in cancer research models. This dossier-guided article provides formulation, treatment, readout, and quality-control practices for in vitro work; the compound is not intended for diagnostic, therapeutic, or clinical use.

• Berberine, SIRT6-AMPK, and Atrial Fibrillation

  2026-08-10

  The reference study identifies SIRT6-AMPK signaling as a protective mechanism against angiotensin II-induced atrial remodeling and atrial fibrillation susceptibility. Using human atrial evidence, bioinformatics, a murine model, and SIRT6 gain- and loss-of-function experiments, it links berberine activity to suppression of NLRP3 inflammasome signaling and oxidative injury.

8591 records 8/573 page Previous Next First page 上5页 678910 下5页 Last page